Monday, 31 August 2026European Markets

BELUGA Stock 10.77% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with BELUGA (BELU.BR) jumping 10.77% to €2.16 on Wednesday, after five consecutive sessions in a row of losses. BEL 20 jumped 0.68% to €3,531.20, after two consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

About BELUGA

Beluga NV is a private equity and venture capital firm specializing in investments in mid venture, late venture, middle market, and mature companies. It also invests in growth capital, later stages, and buyouts. The firm invests across all sectors in companies based in Belgium with a focus on the Flanders region. It usually invests between €0.25 million ($0.37 million) and €2.5 million ($3.75 million) in the form of a minority stake in both public and private companies. The firm typically invests in companies with enterprise value between €1 million ($1.50 million) and €250 million ($375.7 million), sales values between €0.25 million ($0.37 million) and €500 million ($751.41 million), and EBITDA values between €1 million ($1.50 million) and €100 million ($150.28 million). The firm sources its capital through the stock market. Beluga NV was founded in 1998 and is based in Ternat, Belgium.

Earnings Per Share

As for profitability, BELUGA has a trailing twelve months EPS of €0.02.

PE Ratio

BELUGA has a trailing twelve months price to earnings ratio of 108. Meaning, the purchaser of the share is investing €108 for every euro of annual earnings.

More news about BELUGA (BELU.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com